FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2
  • Home
  • About
  • Projects
    • P1 Lymph-Transplant
    • P2 Modulators of LA
    • N1 Ocular GvHD
    • N2 ABCB5 & Pterygium
    • P4 Ocular Melanoma
    • P5 Myeloid Cells
    • P6 Microglia in AMD
    • P8 Uveitis
    • C1 Eye Imaging
    • C2 Management
  • Team
    • Executive Board
    • Research Groups
    • Central Projects
    • Associated projects
    • Alumni
  • Publications
  • Links
  • News
✕

Top international researcher as guest

Prof. Sapieha’s one-week stay in Cologne – sponsored by the Medical Faculty’s Visiting Professor Program – included guest lectures, collaborative talks and a visit to the Pro Retina Foundation’s Science Meeting. Chair Univ. Prof. Dr. Thomas Langmann said, “I am not only enthusiastic about the high quality of Mike Sapieha’s research achievements, including his recent three publications in Science, but also about the translational orientation of his research.” Prof. Sapieha founded the biotech company SemaThera and is Chief Scientific Officer of Unity Biotech, which is already conducting clinical trials in AMD and diabetic retinopathy.

Therapeutic inhibition of immune-mediated senescence in the eye, a key mechanism of aging, represents a completely new approach to the treatment of retinal eye diseases. The Cologne Chair thus has a strong research partner from Canada to implement its own ideas on immunomodulation in the eye at the highest international level. The first successes of this cooperation recently led to a joint Science study in which the harmful role of obesity on the immune system in AMD was elucidated.

Related posts

April 23, 2025

SFB 1607 Launches Website and Celebrates TEO-C New Lab Location


Read more
April 23, 2025

New SFB 1607 Launched – Building on the Foundations of FOR2240


Read more

Fakultaetspreise 2024

February 27, 2024

Faculty prize for PD Dr. Schrittenlocher – Awarded for best habilitation in 2022


Read more

News

  • SFB 1607 Launches Website and Celebrates TEO-C New Lab Location
  • New SFB 1607 Launched – Building on the Foundations of FOR2240
  • Faculty prize for PD Dr. Schrittenlocher – Awarded for best habilitation in 2022
  • DOG poster award for Dr. Martina Maaß
  • Young Cologne Eye Researcher Šejla Gegić won Margarete Kramer Prize

More information

  • Publication highlights
  • Jobs
  • Contact
  • Impressum
  • Datenschutz

Newest publications

Supplemental Anti Vegf A-Therapy Prevents Rebound…(2020)


Bevacizumab Induces Upregulation of Keratin 3 and VEGFA in Human…(2020)


Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional…(2020)


Contact

Claudia Bock
Management Office
DFG Research Unit FOR2240
Department of Ophthalmology
University of Cologne
Kerpener Str. 62
50937 Cologne, Germany

www.for2240.de

Tel. +49 (0)221 478 32845
Fax. +49 (0)221 478 5094
claudia.bock@uk-koeln.de

Partnerlogos

© 2021 FOR2240 | Online Marketing von Resulted Lübeck
      Um unsere Website für Sie optimal zu gestalten und fortlaufend verbessern zu können, verwenden wir Cookies. Durch die weitere Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Weitere Informationen zu Cookies und insb. der Möglichkeiten, der Verwendung von Cookies zu widersprechen, erhalten Sie in unserer Datenschutzerklärung.SchließenDatenschutzerklärung